Cicletanine

Drug Profile

Cicletanine

Alternative Names: cycletanide

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Ipsen
  • Developer Gilead Sciences; Navitas Pharma
  • Class Antihypertensives; Pyridines; Small molecules
  • Mechanism of Action Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pulmonary arterial hypertension

Most Recent Events

  • 10 Mar 2016 Navitas Pharma and IndiPharm plan the phase I/II CHAMP trial for Hypertension in diabetes (Treatment-experienced) in USA and Malaysia (PO) (NCT02709031)
  • 14 Jan 2016 Phase II development is ongoing in USA
  • 14 Jan 2016 Cicletanine is available for licensing as of 14 Jan 2016 http://www.navitaspharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top